Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis
Axel Petzold(Amsterdam UMC Location Vrije Universiteit Amsterdam), Bernhard Hemmer(TUM Klinikum), Fiona Costello(University of Calgary), Jane Ashworth(University of Minnesota), Elena H. Martínez‐Lapiscina(Hospital Clínic de Barcelona), Ari Green(University of California, San Francisco), Laura J. Balcer(University of Pennsylvania), Elena García‐Martín, Christian Cordano(University of California, San Francisco), Jacqueline Bernard, Andrés Cruz-Herranz, Philipp Albrecht(Universitäts-Herzzentrum Freiburg-Bad Krozingen), Inés González‐Suarez, Randy H. Kardon(University of Iowa), Leslie Benson(Boston Children's Hospital), Graeme C. Black(University of Manchester), Nasrin Asgari(University of Southern Denmark), Christina Fasser, P. Vermersch(Inserm), Ardith Courtney, Pablo Villoslada(University of California, San Francisco), Orhan Aktaş(Heinrich Heine University Düsseldorf), Raed Behbehani(Ibn Sina Hospital), Alexander U. Brandt(University of California, Irvine), Lisanne J. Balk(Amsterdam UMC Location Vrije Universiteit Amsterdam), Daniel Boehringer, Joachim Havla(Ludwig-Maximilians-Universität München), Ricarda Diem(Universitätsmedizin Göttingen), Friedemann Paul(Max Delbrück Center), Elliot M. Frohman(The University of Texas Southwestern Medical Center), Jodie Burton, Peter A. Calabresi(Johns Hopkins University), Jennifer Graves(University of California San Diego), Hélène Dollfus(Université de Strasbourg), Sven Schippling(University Hospital of Zurich), Carsten Finke(Humboldt-Universität zu Berlin), Jette Lautrup Frederiksen(University of Copenhagen), Olivier Outteryck(Université Lille Nord de France), Robert Bermel(Cleveland Clinic), Teresa C. Frohman(The University of Texas Southwestern Medical Center), Jonathan Calkwood, Avril Daly, Gorm Pihl-Jensen
Cited by 572
Related Papers
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k
Multiple sclerosis
|The Lancet|2018|1.8k